CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic Analysis Review by GlobalData

VIEWS: 19 PAGES: 25

More Info
									         CardioVascular BioTherapeutics, Inc. (CVBT) - Financial and Strategic
                                 Analysis Review

       Reference Code: GDME8444FSA                                                                                       Publication Date: AUG 2010

       1635 Village Center Circle, Suite Phone                                                        Revenue
                                                                +1 702 8397200                                           0.0 (million USD)
       250
       Las Vegas, NV                     Fax                                                          Net Profit         NA
       89134                                  Website           www.cvbt.com                          Employees          22
       United States                          Exchange          CVBT [Over The Counter]               Industry           Medical Equipment

      Company Overview
       Cardiovascular Biotherapeutics, Inc. (CVBT) is a biopharmaceutical company. It is engaged in the development of protein drugs
       for the treatment of regenerative cardiovascular diseases. The company's development stage product facilitates the growth of
       new blood vessels in the heart, tissues and organs. Its primary product candidate FGF-1 (141), is designed to facilitate the growth
       of new blood vessels in the heart and other tissues and organs with an impaired vascular system and is currently undergoing
       Phase II clinical trials for treatment of coronary heart disease. The company is headquartered in Las Vegas, United States.

      Key Executives                                                                  SWOT Analysis
                     Name                                    Title                    CardioVascular BioTherapeutics, Inc., SWOT Analysis
       Daniel C. Montano                     Chairman                                 Strengths                Weaknesses

       John William Jacobs, PH.D.            Chief Operating Officer
                                                                                                                       Dependence on Single
                                                                                      Agreements
       Mickael A. Flaa                       Chief Financial Officer                                                   Supplier
       Grant Gordon                          Director                                 Proprietary Technology
                                                                                                                       Increased Presence of Debt
       Gary B. Abromovitz                    Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData                                                                     Opportunities                    Threats
      Share Data
                                                                                      Marketing Strategy               Emergence of
       CardioVascular BioTherapeutics, Inc.                                                                            Biogenerics/Biosimilars
       Share Price (USD) as on 26-Mar-2010                                  0.20      Molecules in Clinical
                                                                                      Development                      Tightening of FDA’s Regulatory
       EPS (USD)                                                            -0.27
                                                                                                  
								
To top